Kevin K Brown

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10156639/publications.pdf

Version: 2024-02-01

78 papers	15,468 citations	53660 45 h-index	71532 76 g-index
79 all docs	79 docs citations	79 times ranked	9654 citing authors

#	Article	IF	Citations
1	Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. European Respiratory Journal, 2022, 59, 2004587.	3.1	19
2	Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 313-323.	2.5	21
3	Algorithmic Approach to the Diagnosis of Organizing Pneumonia. Chest, 2022, 162, 156-178.	0.4	13
4	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. Journal of Scleroderma and Related Disorders, 2022, 7, 168-178.	1.0	9
5	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	1.3	15
6	Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology, 2022, 27, 333-340.	1.3	18
7	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 97.	1.4	7
8	Colocalization of Gene Expression and DNA Methylation with Genetic Risk Variants Supports Functional Roles of MUC5B and DSP in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1259-1270.	2.5	12
9	Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Research, 2021, 7, 00805-2020.	1.1	14
10	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. Chest, 2021, 159, 1107-1125.	0.4	53
11	The progressive fibrotic phenotype in current clinical practice. Current Opinion in Pulmonary Medicine, 2021, 27, 368-373.	1.2	7
12	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. Seminars in Arthritis and Rheumatism, 2021, , .	1.6	3
13	The Usefulness of Chest CT Imaging in Patients With Suspected or Diagnosed COVID-19. Chest, 2021, 160, 652-670.	0.4	56
14	Diagnosis and Evaluation of Hypersensitivity Pneumonitis. Chest, 2021, 160, e97-e156.	0.4	104
15	Lung Hyperlucency. Chest, 2020, 157, 119-141.	0.4	3
16	Acute exacerbations of fibrotic interstitial lung diseases. Respirology, 2020, 25, 525-534.	1.3	85
17	Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€”subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respiratory Medicine,the, 2020, 8, 453-460.	5.2	331
18	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respiratory Medicine,the, 2020, 8, 726-737.	5.2	279

#	Article	IF	Citations
19	Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?. European Respiratory Journal, 2020, 55, 1802465.	3.1	25
20	Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest, 2020, 158, 646-659.	0.4	79
21	Clinical Decision-Making in Hypersensitivity Pneumonitis: Diagnosis and Management. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 214-228.	0.8	11
22	The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2020, 55, 2000085.	3.1	148
23	Reply to comment on "The natural history of progressive fibrosing interstitial lung diseases". European Respiratory Journal, 2020, 56, .	3.1	0
24	The NHLBI LAM Registry. Chest, 2019, 155, 288-296.	0.4	67
25	Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 12-21.	2.5	102
26	MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis. Thorax, 2019, 74, 1131-1139.	2.7	43
27	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2019, 381, 1718-1727.	13.9	1,338
28	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. Advances in Therapy, 2019, 36, 3059-3070.	1.3	4
29	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respiratory Research, 2019, 6, e000422.	1.2	79
30	The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities. American Journal of the Medical Sciences, 2019, 357, 405-410.	0.4	1
31	Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes. American Journal of the Medical Sciences, 2019, 357, 359-369.	0.4	45
32	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	5.2	739
33	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
34	What's in a name? That which we call IPF, by any other name would act the same. European Respiratory Journal, 2018, 51, 1800692.	3.1	226
35	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 22-32.	5.2	200
36	Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170050.	3.0	54

#	Article	IF	Citations
37	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respiratory Research, 2017, 4, e000212.	1.2	151
38	Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. Annals of the American Thoracic Society, 2017, 14, 1646-1654.	1.5	77
39	Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Related Outcome Measures, 2016, 7, 29.	0.7	17
40	Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSISÂ® trials. Respiratory Medicine, 2016, 113, 74-79.	1.3	335
41	Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respiratory Medicine, 2016, 119, 150-154.	1.3	111
42	COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No. Chest, 2016, 150, 276-278.	0.4	9
43	Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2016, 47, 588-596.	3.1	277
44	Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1151-1160.	2.5	68
45	Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 491-498.	0.4	75
46	Clinical Characteristics of Connective Tissue Disease-Associated Interstitial Lung Disease in 1,044 Chinese Patients. Chest, 2016, 149, 201-208.	0.4	58
47	Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. Heart and Vessels, 2016, 31, 939-946.	0.5	51
48	Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight, 2016, 1, .	2.3	73
49	CT Scan Findings of Probable Usual Interstitial Pneumonitis Have a High Predictive Value for Histologic Usual Interstitial Pneumonitis. Chest, 2015, 147, 450-459.	0.4	144
50	Supplemental oxygen users with pulmonary fibrosis perceive greater dyspnea than oxygen non-users. Multidisciplinary Respiratory Medicine, 2015, 10, 37.	0.6	7
51	Advances in the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 2015, 20, 537-552.	1.0	8
52	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respiratory Medicine,the, 2015, 3, 388-396.	5.2	69
53	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	3.1	48
54	Definitions of disease: Should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?. Respiratory Investigation, 2015, 53, 88-92.	0.9	5

#	Article	IF	Citations
55	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. European Respiratory Journal, 2015, 46, 1740-1750.	3.1	97
56	Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. European Respiratory Journal, 2015, 46, 512-520.	3.1	164
57	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	3.1	803
58	Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. European Respiratory Journal, 2015, 46, 1370-1377.	3.1	129
59	Fibrotic hypersensitivity pneumonitis. Current Respiratory Care Reports, 2014, 3, 170-178.	0.6	11
60	Smoking-related idiopathic interstitial pneumonia. European Respiratory Journal, 2014, 44, 594-602.	3.1	36
61	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2071-2082.	13.9	3,351
62	Study Design Implications of Death and Hospitalization as End Points in Idiopathic Pulmonary Fibrosis. Chest, 2014, 146, 1256-1262.	0.4	28
63	Preface. Immunology and Allergy Clinics of North America, 2012, 32, xi-xii.	0.7	0
64	Minor Salivary Gland Biopsy To Detect Primary SjÃ¶gren Syndrome in Patients With Interstitial Lung Disease. Chest, 2009, 136, 1072-1078.	0.4	47
65	Heart Rate Recovery After 6-Min Walk Test Predicts Survival in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2009, 136, 841-848.	0.4	90
66	Seasonal Variation. Chest, 2009, 136, 16-22.	0.4	37
67	Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis. Chest, 2009, 135, 1557-1563.	0.4	189
68	Clinically Significant Interstitial Lung Disease in Limited Scleroderma. Chest, 2008, 134, 601-605.	0.4	136
69	Acute Exacerbations of Fibrotic Hypersensitivity Pneumonitis. Chest, 2008, 134, 844-850.	0.4	84
70	Roger S. Mitchell Lecture. Rheumatoid Lung Disease. Proceedings of the American Thoracic Society, 2007, 4, 443-448.	3.5	168
71	Response. Chest, 2007, 131, 940-941.	0.4	0
72	Respiratory Bronchiolitis-Interstitial Lung Disease. Chest, 2007, 131, 664-671.	0.4	104

#	Article	IF	Citations
73	Pulmonary Vasculitis. Proceedings of the American Thoracic Society, 2006, 3, 48-57.	3.5	106
74	Fibrose pulmonar idiopÃ¡tica: uma dÃ©cada de progressos. Jornal Brasileiro De Pneumologia, 2006, 32, 249-260.	0.4	2
75	Update in the Diagnosis and Management of Pulmonary Vasculitis. Chest, 2006, 129, 452-465.	0.4	138
76	Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects. Clinics in Chest Medicine, 2004, 25, 759-772.	0.8	18
77	Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 538-542.	2.5	664
78	Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1025-1032.	2.5	562